COPENHAGEN (Reuters) – Danish medical equipment maker Coloplast has agreed to buy Iceland-based biologic wound care firm Kerecis for up to $1.3 billion, it said on Friday.
Coloplast said it would finance the acquisition of Kerecis, which makes wound care based on fish skin, through an equity capital raise.
“Kerecis represents an attractive opportunity to strategically strengthen Coloplast’s presence in the advanced wound care market by entering the high-growth, US-centric biologics segment,” it said in a statement.
Coloplast said it expected the acquisition to be margin dilutive in the short term but increasingly earnings accretive from 2026 to 2027 onwards.
As a result of the deal, Coloplast raises its long-term organic growth guidance to 8-10% from 7-9% previously, it said.
(Reporting by Louise Breusch Rasmussen, editing by Anna Ringstrom)
